Biocardia CEO Peter Altman buys $555 in widespread inventory

In a latest submitting with the Securities and Trade Fee, BioCardia, Inc. (NASDAQ:BCDA) disclosed that its President and CEO, Peter Altman, bought extra shares of the corporate’s widespread inventory. On December 5, Altman acquired 250 shares at a mean worth of $2.22 per share, amounting to a complete transaction worth of $555. Following this acquisition, Altman now immediately owns 105,581 shares of BioCardia. The micro-cap firm, at the moment valued at $10.6 million, maintains a robust stability sheet with additional cash than debt, in response to InvestingPro knowledge.

The acquisition was executed in a number of trades, with costs starting from $2.17 to $2.24 per share. The weighted common worth is reported as $2.22 per share. This transaction displays Altman’s continued funding within the firm, the place he holds each directorial and government officer roles. The acquisition comes as BioCardia’s inventory has declined over 77% previously yr, with the present worth properly under its 52-week excessive of $10.79. For complete insider buying and selling evaluation and extra monetary insights, buyers can entry the complete Professional Analysis Report on InvestingPro, which covers over 1,400 US shares.

In different latest information, BioCardia, a biotechnology firm, is making important strides in its CardiAMP cell remedy trials for coronary heart failure. The therapeutic asset, BCDA-01, is nearing registration in Japan for treating ischemic coronary heart failure, following a promising session with the Pharmaceutical (TADAWUL:2070) and Medical (TASE:PMCN) System Company (PMDA) of Japan. Regardless of dealing with monetary challenges, together with a considerable income decline and speedy money burn charge, the corporate managed to strengthen its money place following a public providing that raised $7.2 million.

These latest developments additionally embrace the CardiAMP Coronary heart Failure II trial’s growth to accommodate extra sufferers. BioCardia’s strategic plans contain launching its therapies in Japan, leveraging regulatory benefits to expedite the method. Moreover, the corporate plans to finish key goals by the tip of 2024, together with knowledge lock on the CardiAMP Coronary heart Failure I trial and activating extra facilities for the CardiAMP Coronary heart Failure II trial.

The corporate’s monetary well being has additionally improved, with a lower in internet loss to $1.7 million. BioCardia’s BCDA-01 has obtained Breakthrough Designation from the FDA Middle for Organic Analysis and Analysis, additional validating its potential. The corporate’s latest progress and strategic plans recommend a dedication to overcoming its challenges and attaining success within the coming years.

This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.